Eurofins Scientific SE Stock OTC Markets
Stocks
ERFSF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.33 USD | -0.27% |
|
+3.62% | +12.32% |
| 07-23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Eurofins Scientific: BioPharma's slowdown raises questions on 2026 organic growth target |  |
| Market Cap | 12.16B 14.05B 11.36B 10.39B 19.57B 1,340B 19.88B 133B 52.29B 670B 52.74B 51.59B 2,232B | P/E 2026 * |
23.3x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 15.51B 17.91B 14.49B 13.25B 24.96B 1,708B 25.35B 170B 66.7B 855B 67.26B 65.8B 2,847B | EV / Sales 2026 * |
2.04x | EV / Sales 2027 * | 1.89x |
| Free-Float |
60.39% | Yield 2026 * |
1.15% | Yield 2027 * | 1.31% |
Last Transcript: Eurofins Scientific SE
| 1 day | -0.27% | ||
| 1 week | +3.62% | ||
| Current month | +4.18% | ||
| 1 month | +2.39% | ||
| 3 months | +20.95% | ||
| 6 months | +0.70% | ||
| Current year | +12.32% |
| 1 week | 79.57 |  | 83.17 |
| 1 month | 72.78 | | 83.17 |
| Current year | 64.95 | | 86.2 |
| 1 year | 64.95 | | 86.2 |
| 3 years | 44.61 | | 86.2 |
| 5 years | 44.61 | | 151.96 |
| 10 years | 44.61 | | 879.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.27% | +3.62% | - | - | 14.01B | |
| +1.29% | +3.46% | +6.43% | +16.36% | 49.47B | |
| +0.89% | +13.44% | +491.34% | +594.30% | 43.97B | |
| +3.08% | +14.42% | +24.57% | +81.39% | 39.6B | |
| +1.38% | +3.70% | +34.54% | +9.11% | 39.29B | |
| +0.85% | +10.32% | +21.22% | +47.64% | 32.43B | |
| +0.08% | +5.00% | - | - | 16.84B | |
| +1.99% | +5.08% | +38.70% | +125.08% | 16.49B | |
| +0.34% | +3.40% | +5.39% | +18.79% | 14.01B | |
| +3.56% | +19.98% | +86.23% | +27.29% | 12.77B | |
| Average | +1.32% | +7.32% | +88.55% | +115.00% | 29.43B | |
| Weighted average by Cap. | +1.39% | +7.06% | +107.88% | +140.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.59B 8.77B 7.1B 6.49B 12.22B 836B 12.41B 83.21B 32.65B 418B 32.93B 32.21B 1,394B | 8.01B 9.26B 7.49B 6.85B 12.9B 883B 13.1B 87.83B 34.46B 442B 34.76B 34B 1,471B |
| Net income | 532M 615M 497M 455M 857M 58.64B 870M 5.83B 2.29B 29.33B 2.31B 2.26B 97.7B | 661M 764M 618M 565M 1.06B 72.83B 1.08B 7.25B 2.84B 36.43B 2.87B 2.8B 121B |
| Net Debt | 3.35B 3.87B 3.13B 2.86B 5.39B 369B 5.48B 36.7B 14.4B 185B 14.52B 14.21B 615B | 3.01B 3.48B 2.82B 2.57B 4.85B 332B 4.93B 33.02B 12.96B 166B 13.07B 12.78B 553B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-10 | US$82.33 | -0.27% | 965 |
| 26-08-07 | US$82.55 | +1.68% | 287 |
| 26-08-06 | US$81.19 | +1.11% | 10,116 |
| 26-08-05 | US$80.30 | -0.78% | 2,840 |
| 26-08-04 | US$80.93 | +1.86% | 872 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
- ERFSF Stock
Select your edition
All financial news and data tailored to specific country editions
